Valuation: Black Diamond Therapeutics, Inc.

Market Cap 103M 89.64M 82.71M 76.24M 144M 9.88B 147M 989M 389M 4.84B 385M 377M 16.65B P/E 2026 *
-2.76x
P/E 2027 * -1.78x
Enterprise Value 103M 89.64M 82.71M 76.24M 144M 9.88B 147M 989M 389M 4.84B 385M 377M 16.65B EV / Sales 2026 *
18.5x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day-1.10%
1 week-6.28%
Current month-3.24%
1 month+7.83%
3 months-41.50%
6 months-30.08%
Current year-26.34%
1 week 1.76
Extreme 1.76
1.98
1 month 1.6
Extreme 1.6
2.22
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
10.5
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 49 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
26/6/26 Free

Director

40,000 0.0698%
26/6/26 Free

Director

40,000 0.0698%
26/6/26 Free

Director

40,000 0.0698%
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%-6.28%-42.81%-63.17% 103M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.60%-2.99%+32.21%+159.32% 23.37B
Weighted average by Cap. -2.80%-2.36%+39.51%+143.04%

Financials

2026 *2027 *
Net sales 5.56M 4.86M 4.48M 4.13M 7.78M 535M 7.96M 53.55M 21.06M 262M 20.86M 20.41M 902M -
Net income -40.47M -35.37M -32.64M -30.08M -56.7M -3.9B -57.96M -390M -153M -1.91B -152M -149M -6.57B -70.04M -61.21M -56.48M -52.07M -98.13M -6.75B -100M -675M -266M -3.3B -263M -257M -11.37B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
17/07/26 US$1.790 -1.10% 708,209
16/07/26 US$1.810 0.00% 855,858
15/07/26 US$1.810 -2.69% 839,514
14/07/26 US$1.860 -2.11% 609,905
13/07/26 US$1.900 -0.52% 840,826
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.790USD
Average target price
9.857USD
Spread / Average Target
+450.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock